Skip to main content
FTRE logo

FTRE · Fortrea Holdings Inc.

$17.73 -0.03 (-0.17%) At close · Jul 20
Market Cap
$1.68B
Shares
94.60M

Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.

Revenue
$2.72B +1%
FY2025 Revenue FY2021–FY2025
Net Income
-$986.2M -200.2%
FY2025 Net Income FY2021–FY2025
Operating Margin
-32.04% -26pp
FY2025 Operating Margin FY2021–FY2025
Diluted EPS
-$10.81 -194.6%
FY2025 Diluted EPS FY2021–FY2025
Operating Cash Flow
$113.5M -56.8%
FY2025 Operating Cash Flow FY2021–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item TTM FY2025 FY2024 FY2023 FY2022 FY2021
$2.71B $2.72B $2.7B $2.84B $2.84B $3.06B
-$104.1M -$69.7M -$200K
$435.1M $456.4M $560.7M $448.1M $416.1M $303.1M
$58.3M $60.8M $60.7M $62.5M $140M
$78.3M $78M $86.9M $98M $93.6M $166.3M
$33.6M $42M $21.2M $27.7M $16.8M
$3.06B $3.6B $2.86B $2.81B $2.65B $2.94B
-$355.9M -$872.6M -$161.9M $32M $187.1M $114.3M
-32.04% -6% 1.13% 6.59% 3.74%
-$277.6M -$794.6M -$75M $130M $280.7M $280.6M
$69.8M $200K $200K
$8.4M $7.9M $21.3M $6.9M $2.1M $2.1M
-$447.3M -$983M -$275M -$30.5M $187M $136.4M
-$400K $3.2M -$3.5M $1.2M $41.1M $38.4M
-$446.9M -$986.2M -$328.5M -$25.2M $186.2M $98M
-36.21% -12.18% -0.89% 6.56% 3.21%
-$404.1M -$873.3M -$395.9M $34.1M $59.5M $70M
USD/shares -$10.81 -$3.67 -$0.29 $2.09 $1.10
USD/shares -$10.81 -$3.67 -$0.29 $2.09 $1.10
shares 89.5M 88.8M 88.8M 88.8M
shares 89.5M 88.8M 88.8M 88.8M
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
0.95×
Biotechnology median 8.46×
EV/EBIT
Biotechnology median 26.45×
P/E (TTM)
Biotechnology median 7.03×

Valuation over time computed as of each quarter's filing date

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Segment (USD)

Component FY2025 FY2024 FY2023 FY2022 FY2021
Clinical Services Segment $2,723,400,000 $2,696,400,000 $2,842,500,000 $2,837,000,000 $2,763,500,000
Enabling Services Segment $294,000,000

By Geography (USD)

Component FY2025 FY2024 FY2023 FY2022 FY2021
North America $1,289,600,000 $1,269,500,000 $1,398,400,000 $1,415,500,000 $1,649,600,000
Europe $851,700,000 $800,000,000 $827,500,000 $841,900,000 $868,400,000
Other Geographical Areas $582,100,000 $626,900,000 $616,600,000 $579,600,000 $539,500,000

Segment Operating Income

Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.

By Segment (USD)

Component FY2025 FY2024 FY2023 FY2022 FY2021
Clinical Services Segment -$872,600,000 -$161,900,000 $32,000,000 $187,100,000 $339,500,000
Enabling Services Segment $39,000,000

Operating Margin by Segment (%)

Component FY2025 FY2024 FY2023 FY2022 FY2021
Clinical Services Segment -32% -6% 1.1% 6.6% 12.3%
Enabling Services Segment 13.3%
Key facts CIK 1965040 CUSIP 34965K107 13F (30d) 47 filings 46 filers Visit website Investor relations